Does Anyone Really Know What Price It Is? It should be no surprise that Quallent Pharmaceuticals, the specialty distributor subsidiary of Evernorth, has decided to offer their private-label version of ustekinumab at neither a high nor a low wholesale acquisition cost (WAC). The private-label drug, which is based on Samsung Bioepis’ product, is being sold … Continue reading Quallent’s Questionable Ustekinumab Biosimilar Pricing, and Enbrel Price Ceiling in the Rockies